Drinda(SZ:002865) BOCOM International·2025-10-30 01:59Group 1: 恒瑞医药 - The company reported a revenue of 7.43 billion yuan in Q3 2025, representing a year-on-year growth of 12.7%. The contribution of innovative drug revenue exceeded 55% in the first three quarters of 2025 [1][2] - Management expenses increased significantly, leading to a slight decline in net profit margin by 0.5 percentage points to 17.5%. The company recorded an unrealized foreign exchange loss of 150 million yuan related to the depreciation of the US dollar [1] - Operating cash flow increased significantly by 209.8% year-on-year to 4.81 billion yuan, aided by upfront payments from major transactions with GSK and Braveheart. Contract liabilities surged from 161 million yuan in Q2 2025 to 3.97 billion yuan [1] Group 2: 安踏 - The company experienced weak revenue performance in Q3 2025, prompting management to lower the full-year guidance. Anta/FILA and other brands recorded low single-digit year-on-year revenue growth [3][4] - Management has adjusted the growth guidance for the main brand to low single-digit growth, while maintaining the guidance for FILA and other brands at mid-single-digit and over 40% growth, respectively [3] - Future revenue forecasts have been slightly reduced by 1-3%, and net profit forecasts have been lowered by 5-10% based on more conservative profit margin estimates [3] Group 3: 钧达股份 - The company reported a loss of 155 million yuan in Q3 2025, remaining stable compared to the previous quarter. The rise in upstream silicon wafer prices and silver prices has increased non-silicon costs [8] - The Indian Ministry of Commerce announced a final anti-dumping tax recommendation of 23% on imported battery cells from China, which may impact the company's exports [8] - The target price has been adjusted down to 46.34 yuan, corresponding to a 13.3 times 2026 price-to-earnings ratio, while maintaining a buy rating due to attractive valuation after the stock price correction [8] Group 4: 福莱特玻璃 - The company reported Q3 2025 revenue of 4.73 billion yuan and profit of 376 million yuan, with a quarter-on-quarter increase of 29% and 143%, respectively. This was driven by significant inventory accumulation by component customers anticipating a rebound in photovoltaic glass prices [9] - However, industry inventory days have rapidly rebounded since October, leading to expectations of a price decline for glass starting in November [9] - The target price has been raised to 12.05 HKD, but the rating has been downgraded to neutral due to limited attractiveness after recent stock price rebounds [9]